Grace Halsey

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

Peter McAllister, MD,

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

Neurologist and clinical investigator Peter McAllister, MD, is eager to make progress in research on diagnosis and treatment and to hear more patient voices.

Weekly SC injection of lecanemab is expected to maintain clinical and biomarker benefits reached during the IV initiation phase. The PDUFA date is Aug 31, 2025.

Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

Migraine expert Peter McAllister, MD, a long-time principal investigator for migraine studies, wonders if study design in this area needs to be re-evaluated.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

"This AHS statement has exceeded our wildest dreams..." McAllister said of the impact of the society recommendation that CGRP inhibitors be considered among first-line treatment for migraine.

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

The first US interdisciplinary evaluation guideline will help primary care clinicians address the rising prevalence of AD and ADRD seen in their front-line clinical setting.

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

Significant strides were made in 2024 in evaluating a wide range of treatments for migraine, including phase 2 findings with PACAP inhibition, PI McAllister said.

The first study to quantify lecanemab-captured Aβ-PF species in human CSF shows a strong correlation with neurodegeneration and may help explain the drug's MOA.

The bird flu threat remains low, according to public health authorities, but awareness and vigilance will help keep it that way. Here are 9 things you need to know.

The first death of an American from the H5N1 virus was reported in Louisiana on Monday, though authorities maintain the risk of widespread infection remains low.

The onset of migraine with its wide range of symptoms may be telegraphed as early as 2 days before by the frequency of neuronal oscillation deep in the brain.

The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.

Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.

The new chemical entity from Xgene Pharmaceuticals, XG005, targets both anti-nociceptive and anti-neuropathic pain pathways.

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

Axsome plans to submit a New Drug Application to the FDA in the second half of 2025 that is based on positive results from 4 pivotal phase 3 clinical trails and long-term data.

Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.